Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor
Abstract
:1. Introduction
2. Results
2.1. Patient Characteristics
2.2. Serum Ang2 Levels and Autoantibodies against AT1R and ETAR
2.3. Non-Relapse Mortality—All Patients
2.4. Outcome of Patients with TMA
2.5. Autoantibodies against AT1R and GVHD-Manifestations
3. Discussion
4. Materials and Methods
4.1. Patients and Study Design
4.2. Ang2 and Antibodies against AT1R and ETAR
4.3. Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kumpers, P.; David, S.; Haubitz, M.; Hellpap, J.; Horn, R.; Brocker, V.; Schiffer, M.; Haller, H.; Witte, T. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Ann. Rheum. Dis. 2009, 68, 1638–1643. [Google Scholar] [CrossRef] [PubMed]
- Tatekawa, S.; Kohno, A.; Ozeki, K.; Watamoto, K.; Ueda, N.; Yamaguchi, Y.; Kobayashi, T.; Yokota, I.; Teramukai, S.; Taniwaki, M.; et al. A Novel Diagnostic and Prognostic Biomarker Panel for Endothelial Cell Damage–Related Complications in Allogeneic Transplantation. Biol. Blood Marrow Transplant. 2016, 22, 1573–1581. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ueda, N.; Chihara, D.; Kohno, A.; Tatekawa, S.; Ozeki, K.; Watamoto, K.; Morishita, Y. Predictive Value of Circulating Angiopoietin-2 for Endothelial Damage–Related Complications in Allogeneic Hematopoietic Stem Cell Transplantation. Biol. Blood Marrow Transplant. 2014, 20, 1335–1340. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dietrich, S.; Falk, C.S.; Benner, A.; Karamustafa, S.; Hahn, E.; Andrulis, M.; Hegenbart, U.; Ho, A.D.; Dreger, P.; Luft, T. Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft-versus-Host Disease and Response to Steroid Treatment. Biol. Blood Marrow Transplant. 2012, 19, 22–27. [Google Scholar] [CrossRef] [Green Version]
- Dzau, V.J. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001, 37, 1047–1052. [Google Scholar] [CrossRef] [Green Version]
- Madsen, K.; Marcussen, N.; Pedersen, M.; Kjaersgaard, G.; Facemire, C.; Coffman, T.M.; Jensen, B.L. Angiotensin II promotes development of the renal microcirculation through AT1 receptors. J. Am. Soc. Nephrol. 2010, 21, 448–459. [Google Scholar] [CrossRef] [Green Version]
- Horinouchi, T.; Terada, K.; Higashi, T.; Miwa, S. Endothelin receptor signaling: New insight into its regulatory mechanisms. J. Pharmacol. Sci. 2013, 123, 85–101. [Google Scholar] [CrossRef] [Green Version]
- Kurosaka, M.; Suzuki, T.; Hosono, K.; Kamata, Y.; Fukamizu, A.; Kitasato, H.; Fujita, Y.; Majima, M. Reduced angiogenesis and delay in wound healing in angiotensin II type 1a receptor-deficient mice. Biomed. Pharmacother. 2009, 63, 627–634. [Google Scholar] [CrossRef]
- Dragun, D.; Muller, D.N.; Brasen, J.H.; Fritsche, L.; Nieminen-Kelha, M.; Dechend, R.; Kintscher, U.; Rudolph, B.; Hoebeke, J.; Eckert, D.; et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 2005, 352, 558–569. [Google Scholar] [CrossRef] [Green Version]
- Banasik, M.; Boratynska, M.; Koscielska-Kasprzak, K.; Kaminska, D.; Zmonarski, S.; Mazanowska, O.; Krajewska, M.; Bartoszek, D.; Zabinska, M.; Myszka, M.; et al. Non-HLA antibodies: Angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss. Transplant. Proc. 2014, 46, 2618–2621. [Google Scholar] [CrossRef]
- Hiemann, N.E.; Meyer, R.; Wellnhofer, E.; Schoenemann, C.; Heidecke, H.; Lachmann, N.; Hetzer, R.; Dragun, D. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012, 94, 919–924. [Google Scholar] [CrossRef]
- Philogene, M.C.; Bagnasco, S.; Kraus, E.S.; Montgomery, R.A.; Dragun, D.; Leffell, M.S.; Zachary, A.A.; Jackson, A.M. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies. Transplantation 2017, 101, 608–615. [Google Scholar] [CrossRef] [Green Version]
- Wallukat, G.; Pruss, H.; Muller, J.; Schimke, I. Functional autoantibodies in patients with different forms of dementia. PLoS ONE 2018, 13, e0192778. [Google Scholar] [CrossRef]
- Zhang, S.; Zheng, R.; Yang, L.; Zhang, X.; Zuo, L.; Yang, X.; Bai, K.; Song, L.; Tian, J.; Yang, J.; et al. Angiotensin type 1 receptor autoantibody from preeclamptic patients induces human fetoplacental vasoconstriction. J. Cell. Physiol. 2013, 228, 142–148. [Google Scholar] [CrossRef]
- Wang, Y.; Del Borgo, M.; Lee, H.W.; Baraldi, D.; Hirmiz, B.; Gaspari, T.A.; Denton, K.M.; Aguilar, M.I.; Samuel, C.S.; Widdop, R.E. Anti-fibrotic Potential of AT(2) Receptor Agonists. Front. Pharmacol. 2017, 8, 564. [Google Scholar] [CrossRef] [Green Version]
- Lukitsch, I.; Kehr, J.; Chaykovska, L.; Wallukat, G.; Nieminen-Kelha, M.; Batuman, V.; Dragun, D.; Gollasch, M. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 2012, 94, 8–13. [Google Scholar] [CrossRef]
- Reinsmoen, N.; Lai, C.-H.; Heidecke, H.; Haas, M.; Cao, K.; Ong, G.; Naim, M.; Wang, Q.; Mirocha, J.; Kahwaji, J.; et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010, 90, 1473–1477. [Google Scholar] [CrossRef]
- Taniguchi, M.; Rebellato, L.M.; Cai, J.; Hopfield, J.; Briley, K.P.; Haisch, C.E.; Catrou, P.G.; Bolin, P.; Parker, K.; Kendrick, W.T.; et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am. J. Transplant. 2013, 13, 2577–2589. [Google Scholar] [CrossRef]
- O’Leary, J.; Demetris, A.; Philippe, A.; Freeman, R.; Cai, J.; Heidecke, H.; Smith, C.; Hart, B.; Jennings, L.; Catar, R.; et al. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. Transplantation 2017, 101, 2399–2409. [Google Scholar] [CrossRef]
- Wu, C.; Jin, X.; Tsueng, G.; Afrasiabi, C.; Su, A. BioGPS: Building your own mash-up of gene annotations and expression profiles. Nucleic Acids Res. 2016, 44, D313–D316. [Google Scholar] [CrossRef] [Green Version]
- Ohe, H.; Uchida, Y.; Yoshizawa, A.; Hirao, H.; Taniguchi, M.; Maruya, E.; Yurugi, K.; Hishida, R.; Maekawa, T.; Uemoto, S.; et al. Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation 2014, 98, 105–111. [Google Scholar] [CrossRef] [PubMed]
- Silva-Filho, J.L.; Caruso-Neves, C.; Pinheiro, A.A. Angiotensin II type-1 receptor (AT1R) regulates expansion, differentiation, and functional capacity of antigen-specific CD8(+) T cells. Sci. Rep. 2016, 6, 35997. [Google Scholar] [CrossRef] [PubMed]
- Cabral-Marques, O.; Marques, A.; Melvær Giil, L.; De Vito, R.; Rademacher, J.; Günther, J.; Lange, T.; Humrich, J.; Klapa, S.; Schinke, S.; et al. GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nat. Commun. 2018, 9, 5224. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vythoulkas, D.; Tsirigotis, P.; Griniezaki, M.; Konstantellos, I.; Lazana, I. Endothelial Dysfunction Syndromes after Allogeneic Stem Cell Transplantation. Cancers 2023, 15, 680. [Google Scholar] [CrossRef] [PubMed]
- Luft, T.; Dietrich, S.; Falk, C.; Conzelmann, M.; Hess, M.; Benner, A.; Neumann, F.; Isermann, B.; Hegenbart, U.; Ho, A.D.; et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011, 118, 1685–1692. [Google Scholar] [CrossRef] [Green Version]
- Porkholm, M.; Bono, P.; Saarinen-Pihkala, U.M.; Kivivuori, S.M. Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT. Bone Marrow Transplant. 2013, 48, 50–55. [Google Scholar] [CrossRef] [Green Version]
- Li, A.; Bhatraju, P.K.; Chen, J.; Chung, D.W.; Hilton, T.; Houck, K.; Pao, E.; Weiss, N.S.; Lee, S.J.; Davis, C.; et al. Prognostic Biomarkers for Thrombotic Microangiopathy after Acute Graft-versus-Host Disease: A Nested Case-Control Study. Transplant. Cell. Ther. 2021, 27, 308.e1–308.e8. [Google Scholar] [CrossRef]
- Lefaucheur, C.; Viglietti, D.; Bouatou, Y.; Philippe, A.; Pievani, D.; Aubert, O.; Duong Van Huyen, J.P.; Taupin, J.L.; Glotz, D.; Legendre, C.; et al. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int. 2019, 96, 189–201. [Google Scholar] [CrossRef]
- Xu, Q.; McAlister, V.C.; Leckie, S.; House, A.A.; Skaro, A.; Marotta, P. Angiotensin II type I receptor agonistic autoantibodies are associated with poor allograft survival in liver retransplantation. Am. J. Transplant. 2020, 20, 282–288. [Google Scholar] [CrossRef] [Green Version]
- Gerlach, U.A.; Lachmann, N.; Ranucci, G.; Sawitzki, B.; Schoenemann, C.; Pratschke, J.; Dragun, D.; Pascher, A. Non-HLA Antibodies May Accelerate Immune Responses After Intestinal and Multivisceral Transplantation. Transplantation 2017, 101, 141–149. [Google Scholar] [CrossRef]
- Bradford, K.L.; Pearl, M.; Kohn, D.B.; Weng, P.; Yadin, O.; Bowles, V.; De Oliveira, S.N.; Moore, T.B. AT1R Activating Autoantibodies in Hematopoietic Stem Cell Transplantation. Biol. Blood Marrow Transplant. 2020, 26, 2061–2067. [Google Scholar] [CrossRef]
- Riemekasten, G.; Philippe, A.; Nather, M.; Slowinski, T.; Muller, D.N.; Heidecke, H.; Matucci-Cerinic, M.; Czirjak, L.; Lukitsch, I.; Becker, M.; et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann. Rheum. Dis. 2011, 70, 530–536. [Google Scholar] [CrossRef]
- Gunther, J.; Kill, A.; Becker, M.O.; Heidecke, H.; Rademacher, J.; Siegert, E.; Radic, M.; Burmester, G.R.; Dragun, D.; Riemekasten, G. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res. Ther. 2014, 16, R65. [Google Scholar] [CrossRef] [Green Version]
- Pearl, M.H.; Chen, L.; ElChaki, R.; Elashoff, D.; Gjertson, D.W.; Rossetti, M.; Weng, P.L.; Zhang, Q.; Reed, E.F.; Chambers, E.T. Endothelin Type A Receptor Antibodies Are Associated With Angiotensin II Type 1 Receptor Antibodies, Vascular Inflammation, and Decline in Renal Function in Pediatric Kidney Transplantation. Kidney Int. Rep. 2020, 5, 1925–1936. [Google Scholar] [CrossRef]
- Miedema, J.; Schreurs, M.; van der Sar-van der Brugge, S.; Paats, M.; Baart, S.; Bakker, M.; Hoek, R.; Dik, W.A.; Endeman, H.; Van Der Velden, V.; et al. Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course. Front. Immunol. 2021, 12, 684142. [Google Scholar] [CrossRef]
- Yaguchi, S.; Ogawa, Y.; Shimmura, S.; Kawakita, T.; Hatou, S.; Satofuka, S.; Nakamura, S.; Imada, T.; Miyashita, H.; Yoshida, S.; et al. Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease. PLoS ONE 2013, 8, e64724. [Google Scholar] [CrossRef] [Green Version]
- Papp, M.; Li, X.; Zhuang, J.; Wang, R.; Uhal, B.D. Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 282, L713–L718. [Google Scholar] [CrossRef] [Green Version]
- Bataller, R.; Sancho-Bru, P.; Gines, P.; Lora, J.M.; Al-Garawi, A.; Sole, M.; Colmenero, J.; Nicolas, J.M.; Jimenez, W.; Weich, N.; et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003, 125, 117–125. [Google Scholar] [CrossRef]
- Cho, B.S.; Yahng, S.A.; Lee, S.E.; Eom, K.S.; Kim, Y.J.; Kim, H.J.; Lee, S.; Min, C.K.; Cho, S.G.; Kim, D.W.; et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010, 90, 918–926. [Google Scholar] [CrossRef]
- Harris, A.C.; Young, R.; Devine, S.; Hogan, W.J.; Ayuk, F.; Bunworasate, U.; Chanswangphuwana, C.; Efebera, Y.A.; Holler, E.; Litzow, M.; et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol. Blood Marrow Transplant. 2016, 22, 4–10. [Google Scholar] [CrossRef] [Green Version]
- Jagasia, M.H.; Greinix, H.T.; Arora, M.; Williams, K.M.; Wolff, D.; Cowen, E.W.; Palmer, J.; Weisdorf, D.; Treister, N.S.; Cheng, G.S.; et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol. Blood Marrow Transplant. 2015, 21, 389–401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jodele, S.; Dandoy, C.E.; Lane, A.; Laskin, B.L.; Teusink-Cross, A.; Myers, K.C.; Wallace, G.; Nelson, A.; Bleesing, J.; Chima, R.S.; et al. Complement blockade for TA-TMA: Lessons learned from a large pediatric cohort treated with eculizumab. Blood 2020, 135, 1049–1057. [Google Scholar] [CrossRef] [PubMed]
- Luft, T.; Benner, A.; Terzer, T.; Jodele, S.; Dandoy, C.E.; Storb, R.; Kordelas, L.; Beelen, D.; Gooley, T.; Sandmaier, B.M.; et al. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2020, 55, 553–561. [Google Scholar] [CrossRef] [PubMed]
- Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013, 48, 452–458. [Google Scholar] [CrossRef] [Green Version]
Cohorts (1, 2) * | TMA (No = 20 pts) | GVHD w/o TMA (No = 32 pts) | Statistics |
---|---|---|---|
Sex (Male/Female) | 13/7 | 16/16 | p = n.s |
Age, median (range) | 49.5 years, (35–65) | 53.5 years, (27–68) | p = n.s |
Disease (%) AML MDS ALL MPN CLL | 10/20 3/20 5/20 2/20 | 17/32 3/32 6/32 5/32 1/32 | p = n.s |
Donor MUD MMUD MRD | 11/20 5/20 4/20 | 12/32 8/32 12/32 | p = n.s |
Graft source PBSC | 20/20 | 32/32 | p = n.s |
Conditioning MAC RIC | 14/20 6/20 | 21/32 11/32 | p = n.s |
GVHD Moderate Chronic Severe Chronic Acute (grade-II) Severe Acute (III-IV) | 1/20 1/20 9/20 5/20 | 11/32 13/32 12/32 8/32 | p = n.s |
Outcome ** Alive in CR Dead Cause of Death Relapse TMA NRM & | 8/20 12/20 1/20 10/20 1/20 | 18/32 14/32 5/32 NA 9/32 | p = n.s |
Parameter | Hazard Ratio | 95% CI | Significance |
---|---|---|---|
All patients (Cohort 1 and 2) | |||
Serum Ang2 levels (above vs. below the median | 3.298 | 1.168–9.307 | p = 0.024 |
TA-TMA and GVHD vs. GVHD in the absence of TA-TMA | 2.916 | 1.133–7.506 | p = 0.026 |
Only patients with TA-TMA (Cohort 1) | |||
Serum Ang2 levels (above vs. below the median | 7.859 | 1.296–47.650 | p = 0.025 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vythoulkas, D.; Lazana, I.; Kroupis, C.; Gavriilaki, E.; Konstantellos, I.; Bousiou, Z.; Chondropoulos, S.; Griniezaki, M.; Vardi, A.; Gkirkas, K.; et al. Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor. Int. J. Mol. Sci. 2023, 24, 6960. https://doi.org/10.3390/ijms24086960
Vythoulkas D, Lazana I, Kroupis C, Gavriilaki E, Konstantellos I, Bousiou Z, Chondropoulos S, Griniezaki M, Vardi A, Gkirkas K, et al. Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor. International Journal of Molecular Sciences. 2023; 24(8):6960. https://doi.org/10.3390/ijms24086960
Chicago/Turabian StyleVythoulkas, Dionysios, Ioanna Lazana, Christos Kroupis, Eleni Gavriilaki, Ioannis Konstantellos, Zoi Bousiou, Spiros Chondropoulos, Marianna Griniezaki, Anna Vardi, Konstantinos Gkirkas, and et al. 2023. "Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor" International Journal of Molecular Sciences 24, no. 8: 6960. https://doi.org/10.3390/ijms24086960